SCHEMBL2296736

SCHEMBL2296736

Cc1ccc(OC2C[N]C2)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.40
RORC P51449 1/20 0.40
CSNK2A1 P68400 2/20 0.40
FPR2 P25090 6/20 0.39
PROKR1 Q8TCW9 6/20 0.39
MAPT P10636 4/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
RAB9A P51151 2/20 0.39
ATM Q13315 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
ACHE P22303 1/20 0.38
MEN1 O00255 2/20 0.38
MAPK1 P28482 2/20 0.38
KMT2A Q03164 2/20 0.38
HPGD P15428 2/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX12 P18054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299327 0.90 MAPT (0.41) SYKRORCMAPTL3MBTL1RAB9A
SCHEMBL2297174 0.84 FPR2 (0.44) RORCCSNK2A1FPR2PROKR1MAPT
SCHEMBL14294081 0.84 RORC (0.54) SYKRORCCSNK2A1FPR2PROKR1
SCHEMBL12908030 0.81 CSNK2A1 (0.59) SYKRORCCSNK2A1RAB9AHPGD
SCHEMBL13678433 0.81 CSNK2A1 (0.55) SYKRORCCSNK2A1FPR2PROKR1
SCHEMBL14956754 0.79 SLC6A4 (0.53) HTR2CSLC6A4HTR2B
SCHEMBL2299385 0.79 SYK (0.40) SYKL3MBTL1ACHEKMT2ASCN9A
SCHEMBL17708435 0.78 RORC (0.42) SYKRORCCSNK2A1MAPTL3MBTL1
SCHEMBL12908040 0.77 RORC (0.51) SYKRORCCSNK2A1MAPTL3MBTL1
SCHEMBL8042419 0.77 RORC (0.51) SYKRORCCSNK2A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334269-B2 Carboxamides as inhibitors of voltage-gated sodium channels AMGEN INC. (US) 2016-05-10 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
EP-2536689-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN Amgen Inc. (US) 2012-12-26 EP disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS CACNA1B, SCN1A, CACNA1I SYK 3462/4885RORC 4297/4885CSNK2A1 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.